CVRx Reports First Quarter 2025 Financial and Operating Results

About this update from Cvrx, Inc.

[{"type":"image","alt":"CVRx, Inc.","displaySize":"","headline":null,"caption":"CVRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":119,"url":"https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FkSLvnspvArMoZO8.ZuCnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/df09df0c7616e5d7c04e1cae1c854256","width":300,"height":119}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025.","length":353,"tagName":"p"},{"type":"text","content":"Recent Highlights","length":17,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarter","length":106,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. Heart Failure (HF) revenue for the first quarter of 2025 was $11.1 million, an increase of 14% over the prior year quarter","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Active implanting centers in the U.S. grew to 227, an increase of 19% since March 31, 2024","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"Real-world evidence presented at the 2025 THT conference and published in the Journal of Cardiac Failure demonstrated large and statistically significant reductions in hospital visits for patients treated with Barostim","length":218,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":541,"olType":false},{"type":"text","content":""We're encouraged about the momentum building in our business as we move into the second quarter," said Kevin Hykes, President and Chief Executive Officer of CVRx. "While revenue growth in the first quarter didn't meet our expectations, we added a significant number of new sales representatives, and are very pleased with the talent we have attracted to the organization. As these reps are still in the early stages of building their territories, we expect the...

More updates from Cvrx, Inc.